Abstract 2497
Background
Chemotherapy (CT) near end of life is considered a marker of inadequate palliative care for cancer patients. The objectives of our work were to determine the influence of palliative care at home and the distance between the residence area and the cancer referral center on the interval between last chemotherapy cycle and death.
Methods
A retrospective observational study was conducted in a tertiary care hospital. All cancer patients deceased between January 2013 and June 2014 were included. Clinical, demographical and treatment variables were obtained from medical records.
Results
Our population of 951 patients had a mean age of 63 years; male: 601 (63%), females: 350 (37%). Tumor locations: lung, 261 (28%); colorectal, 125 (13%); breast, 99 (10.7%); pancreas, 79 (8.8%). The table shows an analysis of the CT used in all patients, indicating a high proportion of CT use near the end of life (68% in the last 3 months). Average time elapsed between the end of treatment and death was significantly longer in the group of patients included in home palliative care programs (n = 111; 24.5%) vs. those not included (n = 367; 75.5%): 42.3 vs. 24.7 days (p < 0.05). CT was stopped earlier in patients belonging to geographical areas farther from the referral center, with median times between last cycle of CT and death of 14.9 days for patients living near the referral hospital versus 51.9 days for > 70 km (p = 0.041) and 58 days for > 100 km (p = 0.013).Table: 1522P
Analysis of CT use in all patients
| N = 901 | n (%) |
|---|---|
| Treatment No CT CT | 198 (22) 703 (78) |
| Nr of lines of CT 1 2 3 4 or more | 441 (49) 198 (22) 135 (15) 127 (14) |
| Nr of drugs in last line of CT 1 2 3 | 378 (42) 414 (46) 109 (12) |
| CT in the last 3 months | 604 (67) |
| CT in the last 4 weeks | 405 (45) |
| CT in the last week | 63 (7) |
Conclusions
In our population, a high percentage of CT was observed in the final stages of life, including a high use of third and successive lines of treatment. Patients included in home palliative care programs and/or belonging to more distant geographical areas finished active treatment before, thereby suggesting that both factors impact on decision making for patients with advanced cancer. Understanding the factors that determine the use of CT near the end of life may contribute to limit its inadequate indication.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitario Santa Lucia, Cartagena.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract